Rapport Therapeutics, Inc.

Rapport Therapeutics is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on discovering and developing small molecule medicines for central nervous system disorders. The company's therapeutic approach targets specific ion channel and receptor mechanisms implicated in neurological conditions. Its lead candidate, RAP-219, is designed to selectively inhibit a particular class of AMPAR receptors and is being evaluated for focal epilepsy, peripheral neuropathic pain, and bipolar disorder. The company is also advancing RAP-199, a structurally differentiated molecule targeting the same receptor class with alternative pharmacokinetic properties, along with nicotinic acetylcholine receptor programs directed at chronic pain and hearing disorders.

As a pre-commercial entity, Rapport generates no product revenue and operates as a research and development organization. The company maintains a lean operational structure with 69 full-time employees. Incorporated in Delaware in 2022 following its establishment as Precision Neuroscience NewCo, the company rebranded to Rapport Therapeutics in October 2022. Operations are currently concentrated at its Boston headquarters, with clinical development activities ongoing in the United States.